莫西沙星序贯治疗老年急性下呼吸道感染的疗效观察

An observation of moxifloxacin sequential therapy for acute lower respiratory infection in elderly patients

目的观察莫西沙星序贯治疗老年急性下呼吸道感染的疗效。方法选取60例老年中重度急性下呼吸道感染的老年患者,随机分组后,分别给予莫西沙星序贯治疗、莫西沙星静脉治疗及头孢呋辛序贯治疗,比较其临床疗效、细菌清除率及不良反应。结果莫西沙星序贯治疗组与莫西沙星静脉治疗组相比,总有效率(85%与90%)、治愈率(75%与75%)及细菌清除率(88.23%与87.5%)无显著差异(P>0.05),但显著优于头孢呋辛序贯治疗组(65%、50%和68.8%,P<0.05)。3组不良反应发生率均较低,无显著性差异(P>0.05)。结论莫西沙星序贯治疗临床抗感染疗效确切,不良反应轻微,是治疗老年人急性下呼吸道感染较为理想的治疗方法。

Objective To observe the curative effect of moxifloxacin sequential therapy for acute lower respiratory infection in elderly patients. Methods Sixty elderly patients were chosen and divided into 3 groups in random. The groups were treated with moxifloxacin sequential therapy, moxifloxacin venous transfusion and cefuroxime sequential therapy separately. The clinical curative effect, bacteria clearance and side reaction were compared. Results There were not significant difference in general effective power, recovery, rate and bacteria clearance between moxifloxacin venous transfusion and moxifloxacin sequential therapy. But moxifloxacin was better than cefuroxime in clinical curative effect. The side reaction was low in all of the three groups and no significant difference was observed. Conclusions The anti-infection function of moxifloxacin sequential therapy is reliable, and the side reaction of moxifloxacin is light. Moxifloxacin sequential therapy is an ideal method for acute lower respiratory infection in gerontal patients.